Pharmaceuticals

Lishengpharma

Lishengpharma released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 332.28 M, actual EPS CNY 0.2

Lishengpharma to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

Lishengpharma FY2025 Annual Earnings Release on March 25, 2026 After-Market (BJT)

Lishengpharma released FY2025 Q4 earnings on March 9 After-Market (BJT), actual revenue CNY 384.73 M, actual EPS CNY 0.1485

Lishengpharma released FY2025 annual earnings on March 9 After-Market (BJT), actual revenue CNY 1.392 B, actual EPS CNY 1.62

Lishengpharma released FY2025 Q3 earnings on October 23 After-Market BJT, actual revenue CNY 275.77 M, actual EPS CNY 0.1083

Lishengpharma released FY2025 9 Months Earnings on October 23 After-Market (BJT), actual revenue CNY 1.007 B, actual EPS CNY 1.2147

Lishengpharma FY2025 Q3 Earnings Release on October 24, 2025 After-Market (BJT)

Lishengpharma released FY2025 Semi-Annual Earnings on August 21 After-Market BJT, actual revenue CNY 731.51 M, actual EPS CNY 1.1083

Lishengpharma released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 361.67 M, actual EPS CNY 1.1393

Lishengpharma to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Opening Securities Gives Lingsheng Pharmaceutical Buy Rating

Lisheng Pharmaceutical Receives Open Securities Buy Rating, Stock Up 9.98%

Lisheng Pharmaceutical Obtains Drug Registration Certificate

Lisheng Pharmaceutical Anticipates Significant Growth in Net Profit for the First Half of 2025

Tianjin Lisheng Pharmaceutical Sees Revenue Growth But Profits Plunge

Lisheng Pharmaceutical Pays Additional Taxes and Penalties of 35.11 Million Yuan

Lisheng Pharmaceutical Discloses Innovation Drug Strategy and Product Details

Lisheng Pharmaceutical Obtains Drug Registration Certificate for Ticagrelor Dispersible Tablets

Lisheng Pharmaceutical's Subsidiary's Cefaclor Modified Release Tablets Pass Consistency Evaluation

516930

159892

516820

520690

588130

159992

516610

159929

159506

002393

科兴生物制药股份有限公司

512010

510660

520880

159316

UBS has lowered the target price for SINO BIOPHARM to 11 yuan, maintaining a "Buy" rating. The report pointed out that last year the company's revenue was 31.8 billion yuan, a year-on-year increase of 10.3%, which was below expectations; net profit was 2.3 billion yuan, a year-on-year increase of 22%, also below expectations. The gross profit margin rose to 82.1%. Management expects double-digit growth in both revenue and profit this year. Although the earnings per share forecast for this year has been raised by 9.4%, the earnings per share forecasts for 2027 and 2028 have been lowered due to lower expectations for generic drug revenue

AASTOCKS

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

SBP GROUP

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

The next blockbuster BD deal is on its way

- China Biologic Products (01177.HK) reported a 2025 total revenue of 31.83 billion CNY, a year-on-year increase of 10.3%, with adjusted net profit rising 31.4% to 4.54 billion CNY.  
- The company has undertaken significant acquisitions, including a $950 million purchase of Auron Biopharma and a $1.2 billion acquisition of Hegia, positioning itself uniquely in the domestic pharmaceutical market.  
- With a target of launching nearly 20 innovative products by 2028, including advancements in oncology and chronic disease treatment, China Biologic aims for substantial international revenue growth through a dual strategy of acquisitions and global business development.

Wallstreetcn

Bosera Hang Seng Health Care ETF(QDII)

CH BIOTECH SER

GF CSI HK Innovative Drugs Industry ETF(QDII)

Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM

00882

513700

Tianjin Development's indirectly non-wholly-owned subsidiary Lishengpharma announced its full-year results for the year ended last December, with a revenue of RMB 1.392 billion, an increase of 4.2% year-on-year. The net profit was RMB 416 million, an increase of 125.6% year-on-year; earnings per share were RMB 1.62. A cash dividend of RMB 6.00 will be distributed for every 10 shares

TIANJIN DEV

Penghua CSI HK Connect Health Care Composite ETF

Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tip Ranks

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tianjin Development Holdings announced that its subsidiary, Tianjin Lisheng Pharmaceutical, reported strong preliminary results for 2025. Revenue increased by 4.23% year-on-year to RMB1.39 billion, while net profit attributable to shareholders surged 126.72% to RMB418 million. The growth was driven by market expansion and stronger product sales. Despite a slight decline in net assets per share, the results highlight the company's significant stake in China's healthcare market.

Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge

601166

TIANJIN DEV announced that last Wednesday (24th), its indirectly non-wholly-owned subsidiary Lishengpharma entered into the twelfth financial management agreement with INDUSTRIAL BANK, with a principal amount of RMB 85 million to subscribe for another structured deposit. The investment period is 182 days, with an expected annualized yield of 1.2% to 1.6%

INDUSTRIAL BANK

Tianjin Development's subsidiary invests RMB 85 million to subscribe to wealth management products

36Kr learned that Lishengpharma announced that the company's senior management personnel, Guo Xiaoyan, plans to reduce holdings of the company's shares by no more than 11,200 shares through centralized bidding, with the intended reduction not exceeding 0.0044% of the total share capital after excluding the shares in the repurchase special account

36Kr

Lishengpharma: Company executives plan to reduce their holdings by no more than 11,200 shares of the company

According to the Zhitong Finance APP, Lishengpharma disclosed its third-quarter report for 2025. The company achieved a revenue of 1.007 billion yuan in the first three quarters, a year-on-year decrease of 1.61%; the net profit attributable to shareholders of the listed company was 371 million yuan, a year-on-year increase of 119.05%; the net profit excluding non-recurring gains and losses was 127 million yuan, a year-on-year increase of 19.21%; the basic earnings per share were 1.44 yuan

Zhitong

Lishengpharma released its performance for the first three quarters, with a net profit attributable to the parent company of 371 million yuan, a year-on-year increase of 119.05%

Lishengpharma(002393.SZ)

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM

Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge

Tianjin Development's subsidiary invests RMB 85 million to subscribe to wealth management products

Lishengpharma: Company executives plan to reduce their holdings by no more than 11,200 shares of the company

Lishengpharma released its performance for the first three quarters, with a net profit attributable to the parent company of 371 million yuan, a year-on-year increase of 119.05%